News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
The Globe and Mail Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wall Street Zen downgraded Tenet Healthcare (NYSE:THC) from a "strong-buy" to a "buy" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $273. The company recently reported strong quarterly earnings of $6.12 per share, exceeding estimates, with …
SOPHiA GENETICS (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the company's stock on August 13th for $30,080, reducing his position by 0.68%. This sale was part of a pre-arranged Rule 10b5-1 trading plan, and Xu has made several other sales since early July. …
Glenview Capital Management and Larry Robbins have reported that they no longer hold a significant ownership stake in Myriad Genetics (MYGN). An SEC filing (SCHEDULE 13G/A) indicates that as of June 30, 2026, they beneficially own 0 shares, representing 0% of the outstanding common …
Vestal Point Capital, LP and its Chief Investment Officer Ryan Wilder have disclosed a 6.1% stake in Myriad Genetics, Inc. (MYGN) through a Schedule 13G filing. The reporting group beneficially owns 5,735,000 shares of common stock, representing 6.1% of the 94,448,210 outstanding shares as …
Meghan Fitzgerald, Columbia Professor, Grey Ghost Capital Private Equity Investor and on the board of Tenet Healthcare joins Yahoo Finance's Julie Hyman to explain why the U.S. healthcare crisis stems from nurse retention and burnout rather than a labor supply shortage. Video Transcript 00:00 …
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in …
Shares of Tenet Healthcare (THC) have been strong performers lately, with the stock up 34.1% over the past month. The stock hit a new 52-week high of $270.57 in the previous session. Tenet has gained 34.4% since the start of the year compared to …
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Tenet Fintech Group Inc. (CSE: PKK) (OTC Pink: PKKFF) ("Tenet" or the "Company"), an innovative analytics service provider, owner and operator of the Cubeler Business Hub, today announced that it has signed an agreement with Sum …
Tenet Healthcare (THC) has seen a significant surge in its share price and an increase in its 2026 adjusted EPS guidance, leading to questions about its valuation. While some analysts deem it overvalued at $250 compared to its last close of $267.05, others note …
Kirby McInerney LLP is investigating Myriad Genetics, Inc. (NASDAQ: MYGN) following a significant stock price decline after the company reported an 11% year-over-year revenue decrease in Q2 2026 and reduced its full-year guidance. The decline was attributed to issues with payer reimbursement and revenue-cycle …
Myriad Genetics (NASDAQ: MYGN) is facing multiple investor investigations from several law firms after reporting weaker-than-expected second-quarter results and sharply reducing its 2026 revenue outlook. The company's stock lost nearly half its value following the announcement, prompting inquiries into whether Myriad Genetics or its …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Technical signal puts fresh focus on Tenet Healthcare stock Tenet Healthcare (THC) recently triggered a golden cross, as its 50 day simple moving average …
This article first appeared on GuruFocus. Subscription Base: Expanded by 140,000 in the first half of 2026, surpassing 10 million subscribers. Mobile Subscribers: Added 34,000 net new subscribers in Q2 2026. IPTV Subscribers: Added 35,000 net new subscribers in Q2 2026. Postpaid Service Revenue: …
Sharemaestro market context Price below Trend Line 52 weeks -9.7%Zacks Research has upgraded Tenet Healthcare (NYSE:THC) from a "hold" to a "strong-buy" rating. This upgrade comes after Tenet reported strong quarterly earnings, beating analyst estimates with $6.12 earnings per share and revenue of $6.04 billion. Despite recent insider stock sales totaling $9.8 million, …
Dimensional Fund Advisors LP significantly reduced its stake in Myriad Genetics, Inc. by 42.6% in the first quarter, selling over half a million shares. This move comes as institutional investors hold a substantial portion of the company, and analysts have become more bearish, issuing …
Recently, Tenet Healthcare reported a bullish technical "golden cross" alongside higher earnings estimates, while management raised its 2026 adjusted EPS guidance and outlined further investment in its ambulatory care platform. The company's emphasis on higher-acuity services, expanding outpatient capabilities, and strengthened earnings outlook has …
This article highlights bullish sentiments from analysts on three healthcare companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS), and Perspective Therapeutics (CATX). Maxim Group maintained a Buy rating for Atossa, Mizuho Securities reiterated a Buy for Corvus, and LifeSci Capital also maintained a Buy for …
Maxim Group has reiterated its Buy rating for Atossa Therapeutics (ATOS.US) and maintained its price target of $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well. FOMO, or the fear of missing out, …
Assenagon Asset Management S.A. significantly reduced its stake in Myriad Genetics, Inc. by 28.7% in the second quarter, selling over 415,000 shares. This divestment follows Myriad Genetics reporting disappointing quarterly results, missing analyst expectations for both earnings and revenue, and experiencing a year-over-year revenue …
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (NASDAQ: MYGN) securities. This investigation follows Myriad's Q2 2026 revenue report, which showed an 11% year-over-year decrease and fell short of Wall Street estimates, leading the company …
Tenet Healthcare Corporation (THC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, THC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross." A golden cross …
Quantinno Capital Management LP significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the first quarter, bringing its total holdings to 137,479 shares valued at $2.19 million. Institutional investors now own 48.06% of FLGT, while company insiders hold 36.18%, with recent …
Sharemaestro market context Price below Trend Line 52 weeks -6.9% · Next-week setup negative 12.1%Tenet Healthcare (THC) Director Tammy Romo sold 7,422 shares on August 7, 2026, for approximately $1.95 million, reducing her total holdings to 28,284 shares. This transaction is part of a trend of 21 insider sells and zero buys over the past year, suggesting a …
Search by ticker symbol or company name and select a result to open its chart.